Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Knight Therapeutics Inc (KHTRF)

Knight Therapeutics Inc (KHTRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.41
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.6530 +2.11%
on 11/13/24
4.0400 -7.67%
on 10/24/24
-0.3400 (-8.35%)
since 10/21/24
3-Month
3.6530 +2.11%
on 11/13/24
4.5500 -18.02%
on 09/16/24
-0.3800 (-9.25%)
since 08/14/24
52-Week
3.6530 +2.11%
on 11/13/24
4.5500 -18.02%
on 09/16/24
-0.1500 (-3.87%)
since 11/21/23

Most Recent Stories

More News
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 5.21 (+1.76%)
CNCE : 8.37 (+0.12%)
KYKOF : 16.7472 (+0.41%)
SFOSF : 2.0000 (-6.54%)
KHTRF : 3.7300 (+1.00%)
ACIU : 3.37 (+2.45%)
BMEA : 6.64 (+4.08%)

Key Turning Points

3rd Resistance Point 3.7467
2nd Resistance Point 3.7433
1st Resistance Point 3.7367
Last Price 3.7300
1st Support Level 3.7267
2nd Support Level 3.7233
3rd Support Level 3.7167

See More

52-Week High 4.5500
Fibonacci 61.8% 4.2073
Fibonacci 50% 4.1015
Fibonacci 38.2% 3.9957
Last Price 3.7300
52-Week Low 3.6530

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar